These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 26758759)

  • 1. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in oncology: everybody agrees but nobody uses?
    Gyawali B
    Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
    Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
    Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
    Bennett CL; Sartor OA; Armitage JO; Kantarjian H
    Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.
    Azuz S; Newton M; Bartels D; Poulsen BK
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1495-1501. PubMed ID: 34008071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
    Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
    BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.